Celyad Oncology to Present at the 2024 SITC Annual Meeting
Celyad Oncology (Euronext: CYAD) announces two poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, November 6-10, 2024. The first poster (Abstract 262) focuses on PSMA/NKG2DL tandem CAR T-cells to improve anti-tumor efficacy against prostate cancer, to be presented on November 9. The second poster (Abstract 1133) discusses efficient and safe modulation of multiple target genes in CAR T-cells using a miRNA-based shRNA platform, to be presented on November 8.
Both posters will be available in the poster hall and virtually to SITC Annual Meeting registrants from November 7 at 10 a.m. ET. The posters will also be archived on Celyad Oncology's website under the 'Scientific Publications' section.
Celyad Oncology (Euronext: CYAD) annuncia due presentazioni poster al 39° Congresso Annuale della Society for Immunotherapy of Cancer (SITC) che si terrà a Houston, dal 6 al 10 novembre 2024. Il primo poster (Abstract 262) si concentra su CAR T-cell in tandem PSMA/NKG2DL per migliorare l'efficacia anti-tumorale contro il cancro alla prostata, che sarà presentato il 9 novembre. Il secondo poster (Abstract 1133) discute la modulazione efficiente e sicura di più geni bersaglio nelle CAR T-cell utilizzando una piattaforma shRNA basata su miRNA, che sarà presentato l'8 novembre.
Entrambi i poster saranno disponibili nel poster hall e virtualmente per i registrati al Congresso SITC a partire dal 7 novembre alle 10 a.m. ET. I poster saranno anche archiviati sul sito web di Celyad Oncology nella sezione 'Pubblicazioni Scientifiche'.
Celyad Oncology (Euronext: CYAD) anuncia dos presentaciones de póster en la 39ª Reunión Anual de la Society for Immunotherapy of Cancer (SITC) en Houston, del 6 al 10 de noviembre de 2024. El primer póster (Resumen 262) se centra en Células T CAR en tándem PSMA/NKG2DL para mejorar la eficacia antitumoral contra el cáncer de próstata, que se presentará el 9 de noviembre. El segundo póster (Resumen 1133) discute la modulación eficiente y segura de múltiples genes diana en células T CAR utilizando una plataforma shRNA basada en miRNA, que se presentará el 8 de noviembre.
Ambos pósters estarán disponibles en el salón de pósters y virtualmente para los registrados en la Reunión Anual de SITC a partir del 7 de noviembre a las 10 a.m. ET. Los pósters también se archivarían en el sitio web de Celyad Oncology en la sección de 'Publicaciones Científicas'.
셀리야드 온콜로지 (유로넥스트: CYAD)는 2024년 11월 6일부터 10일까지 휴스턴에서 열리는 제39회 암 면역 요법 학회(SITC) 연례 회의에서 두 개의 포스터 발표를 알렸습니다. 첫 번째 포스터 (초록 262)는 전립선 암에 대한 항종양 효능을 향상시키기 위한 PSMA/NKG2DL 탠덤 CAR T세포에 초점을 맞추며, 11월 9일에 발표될 예정입니다. 두 번째 포스터 (초록 1133)는 miRNA 기반 shRNA 플랫폼을 사용하여 CAR T세포에서 여러 목표 유전자의 효율적이고 안전한 조절을 다룹니다. 이는 11월 8일에 발표될 예정입니다.
두 개의 포스터는 11월 7일 오전 10시 ET부터 SITC 연례 회의 등록자에게 포스터 홀과 온라인에서 제공될 예정입니다. 포스터는 또한 '과학 출판물' 섹션에 있는 셀리야드 온콜로지의 웹사이트에 보관될 것입니다.
Celyad Oncology (Euronext: CYAD) annonce deux présentations de posters lors du 39ème Congrès Annuel de la Society for Immunotherapy of Cancer (SITC) à Houston, du 6 au 10 novembre 2024. Le premier poster (Résumé 262) se concentre sur les cellules CAR T en tandem PSMA/NKG2DL pour améliorer l'efficacité anti-tumorale contre le cancer de la prostate, qui sera présenté le 9 novembre. Le second poster (Résumé 1133) discute de la modulation efficace et sécurisée de plusieurs gènes cibles dans les cellules CAR T en utilisant une plateforme shRNA basée sur miRNA, qui sera présenté le 8 novembre.
Les deux posters seront disponibles dans la salle des posters et virtuellement pour les inscrits à la Réunion Annuelle du SITC à partir du 7 novembre à 10 heures ET. Les posters seront également archivés sur le site web de Celyad Oncology dans la section 'Publications Scientifiques'.
Celyad Oncology (Euronext: CYAD) kündigt zwei Posterpräsentationen auf dem 39. Jahresmeeting der Society for Immunotherapy of Cancer (SITC) in Houston vom 6. bis 10. November 2024 an. Das erste Poster (Abstract 262) konzentriert sich auf PSMA/NKG2DL Tandem CAR-T-Zellen, um die antitumorale Wirksamkeit gegen Prostatakrebs zu verbessern, und wird am 9. November präsentiert. Das zweite Poster (Abstract 1133) behandelt die effiziente und sichere Modulation mehrerer Zielgene in CAR-T-Zellen mit einer miRNA-basierten shRNA-Plattform, die am 8. November präsentiert wird.
Beide Poster sind ab dem 7. November um 10 Uhr ET sowohl im Posterraum als auch virtuell für die registrierten Teilnehmer des SITC-Jahrestreffens verfügbar. Die Poster werden auch im Bereich 'Wissenschaftliche Publikationen' auf der Website von Celyad Oncology archiviert.
- None.
- None.
MONT-SAINT-GUIBERT,
Celyad Oncology (Euronext: CYAD) (the “Company”), today announces two poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held in
Poster Presentation Details
- Abstract 262: PSMA/NKG2DL tandem CAR T-cells to overcome antigen heterogeneity and improve anti-tumor efficacy against prostate cancer. To be presented on Saturday, November 9 at the Poster session (Cellular Therapies)
- Abstract 1133: Efficient, safe and customizable modulation of multiple target genes in CAR T-cells through a miRNA-based shRNA platform. To be presented on Friday November 8 at the Poster session (Immuno-Engineering)
Posters will be available in the poster hall and virtually to registrants of the SITC Annual Meeting, beginning Nov. 7 at 10 a.m. ET. Posters will also be archived under “Scientific Publications” in the Science section of the Company’s website located at www.celyad.com.
About Celyad Oncology
Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in Mont-Saint-Guibert,
Celyad Oncology Forward-Looking Statement
This release may contain forward-looking statements, including, without limitation, statements regarding beliefs about and expectations for the Company’s updated strategic business model, including associated potential benefits, transactions and partnerships, statements regarding the potential value of the Company’s IP, and statements regarding the continuation of the Company’s existence. The words “will,” “potential,” “continue,” “target,” “project,” “should” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this release are based on management’s current expectations and beliefs and are subject to a number of known and unknown risks, uncertainties and important factors which might cause actual events, results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks related to the material uncertainty about the Company’s ability to continue as a going concern; the Company’s ability to realize the expected benefits of its updated strategic business model; the Company’s ability to develop its IP assets and enter into partnerships with outside parties; the Company’s ability to enforce its patents and other IP rights; the possibility that the Company may infringe on the patents or IP rights of others and be required to defend against patent or other IP rights suits; the possibility that the Company may not successfully defend itself against claims of patent infringement or other IP rights suits, which could result in substantial claims for damages against the Company; the possibility that the Company may become involved in lawsuits to protect or enforce its patents, which could be expensive, time-consuming, and unsuccessful; the Company’s ability to protect its IP rights throughout the world; the potential for patents held by the Company to be found invalid or unenforceable; and other risks identified in the latest Annual Report and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
Source: Celyad Oncology SA
View source version on businesswire.com: https://www.businesswire.com/news/home/20241004415472/en/
Investor & Media Contact:
David Georges, VP Finance and Administration
investors@celyad.com
Source: Celyad Oncology SA
FAQ
What presentations will Celyad Oncology (CYAD) make at the 2024 SITC Annual Meeting?
When and where will Celyad Oncology's (CYAD) posters be presented at SITC 2024?
How can people access Celyad Oncology's (CYAD) SITC 2024 poster presentations?
What is the focus of Celyad Oncology's (CYAD) Abstract 262 presentation at SITC 2024?